LGALS3 and prostate cancer: Increasing evidence suggests that galectin-3 promotes chemoresistance in prostate cancer, cholangiocarcinoma, thyroid carcinoma [9], lung cancer [5], and ovarian cancer [3, 5] as well as protects BT549 human breast carcinoma cells from apoptosis induced by cisplatin, anthracycline, adriamycin, and 5-FU (5-fluorouracil) [5].